FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285490947> ?p ?o ?g. }

• W4285490947 endingPage "2762" @default.
• W4285490947 startingPage "2751" @default.
• W4285490947 abstract "Immunotherapy (IO) agents have led to significant improvements in patient outcomes across many tumor types. There have been great efforts to introduce immune checkpoint inhibitors into the treatment paradigm of esophagogastric cancers as well. A number of randomized phase III trials, which will be reviewed here, established the role of these agents in both early-stage and advanced-stage disease. Adjuvant nivolumab is US Food and Drug Administration–approved after neoadjuvant chemoradiation and resection of esophageal and gastroesophageal junction cancers on the basis of the phase III CheckMate 577 trial. In the advanced setting, patients with programmed death receptor ligand-1–positive tumors should be recommended IO in combination with chemotherapy in the first-line setting on the basis of the results from KEYNOTE 590, CheckMate 649, and CheckMate 648. Across trials, chemotherapy continues to play a critical role in the first-line setting and should be offered to all patients who are eligible for systemic therapy, including those with biomarker select tumors. In the later lines of treatment, IO has modest activity, and prior studies have grown largely irrelevant because of the enrollment of IO-naive patients. Similar to other disease types, patients with microsatellite unstable (microsatellite instability high) tumors represent a unique cohort that is more sensitive to IO. However, there are no randomized studies evaluating how best to apply IO in early or advanced stages specifically for the treatment of patients with microsatellite instability high upper GI tumors. Questions remain how to best select patients who benefit from IO treatments, how to augment IO activity in programmed death receptor ligand-1–negative tumors, and how to incorporate IO in late-line settings or for recurrent disease that has been treated with IO-containing regimens during early stages." @default.
• W4285490947 created "2022-07-15" @default.
• W4285490947 creator A5004212252 @default.
• W4285490947 creator A5021338173 @default.
• W4285490947 creator A5022835462 @default.
• W4285490947 creator A5073811035 @default.
• W4285490947 creator A5077847168 @default.
• W4285490947 date "2022-08-20" @default.
• W4285490947 modified "2023-10-16" @default.
• W4285490947 title "Esophagogastric Cancers: Integrating Immunotherapy Therapy Into Current Practice" @default.
• W4285490947 cites W2100439220 @default.
• W4285490947 cites W2136197678 @default.
• W4285490947 cites W2154444715 @default.
• W4285490947 cites W2298468092 @default.
• W4285490947 cites W2330169545 @default.
• W4285490947 cites W2529308344 @default.
• W4285490947 cites W2592337042 @default.
• W4285490947 cites W2763064222 @default.
• W4285490947 cites W2767857925 @default.
• W4285490947 cites W2786816161 @default.
• W4285490947 cites W2793364080 @default.
• W4285490947 cites W2806614796 @default.
• W4285490947 cites W2808750176 @default.
• W4285490947 cites W2889646458 @default.
• W4285490947 cites W2906436263 @default.
• W4285490947 cites W2912403850 @default.
• W4285490947 cites W2917253379 @default.
• W4285490947 cites W2938774982 @default.
• W4285490947 cites W2947917218 @default.
• W4285490947 cites W2954591958 @default.
• W4285490947 cites W2970465219 @default.
• W4285490947 cites W2976652879 @default.
• W4285490947 cites W2984359187 @default.
• W4285490947 cites W3010563737 @default.
• W4285490947 cites W3024911178 @default.
• W4285490947 cites W3029999697 @default.
• W4285490947 cites W3080192585 @default.
• W4285490947 cites W3082736986 @default.
• W4285490947 cites W3088611248 @default.
• W4285490947 cites W3089110714 @default.
• W4285490947 cites W3092384992 @default.
• W4285490947 cites W3098108773 @default.
• W4285490947 cites W3113868193 @default.
• W4285490947 cites W3145734939 @default.
• W4285490947 cites W3148827278 @default.
• W4285490947 cites W3154482193 @default.
• W4285490947 cites W3158415488 @default.
• W4285490947 cites W3160377948 @default.
• W4285490947 cites W3161258718 @default.
• W4285490947 cites W3162000319 @default.
• W4285490947 cites W3163562363 @default.
• W4285490947 cites W3167114692 @default.
• W4285490947 cites W3168264157 @default.
• W4285490947 cites W3171517418 @default.
• W4285490947 cites W3172772308 @default.
• W4285490947 cites W3173451714 @default.
• W4285490947 cites W3184843436 @default.
• W4285490947 cites W3194103440 @default.
• W4285490947 cites W3195935456 @default.
• W4285490947 cites W3201914217 @default.
• W4285490947 cites W3203039131 @default.
• W4285490947 cites W3203829896 @default.
• W4285490947 cites W3216738011 @default.
• W4285490947 cites W4200595129 @default.
• W4285490947 cites W4205506118 @default.
• W4285490947 cites W4224213460 @default.
• W4285490947 cites W4226136872 @default.
• W4285490947 cites W4291802844 @default.
• W4285490947 doi "https://doi.org/10.1200/jco.21.02500" @default.
• W4285490947 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35839430" @default.
• W4285490947 hasPublicationYear "2022" @default.
• W4285490947 type Work @default.
• W4285490947 citedByCount "15" @default.
• W4285490947 countsByYear W42854909472022 @default.
• W4285490947 countsByYear W42854909472023 @default.
• W4285490947 crossrefType "journal-article" @default.
• W4285490947 hasAuthorship W4285490947A5004212252 @default.
• W4285490947 hasAuthorship W4285490947A5021338173 @default.
• W4285490947 hasAuthorship W4285490947A5022835462 @default.
• W4285490947 hasAuthorship W4285490947A5073811035 @default.
• W4285490947 hasAuthorship W4285490947A5077847168 @default.
• W4285490947 hasBestOaLocation W42854909472 @default.
• W4285490947 hasConcept C104317684 @default.
• W4285490947 hasConcept C121608353 @default.
• W4285490947 hasConcept C126322002 @default.
• W4285490947 hasConcept C143998085 @default.
• W4285490947 hasConcept C168563851 @default.
• W4285490947 hasConcept C180754005 @default.
• W4285490947 hasConcept C185592680 @default.
• W4285490947 hasConcept C2776694085 @default.
• W4285490947 hasConcept C2777701055 @default.
• W4285490947 hasConcept C2777863537 @default.
• W4285490947 hasConcept C2779134260 @default.
• W4285490947 hasConcept C2779767149 @default.
• W4285490947 hasConcept C2779786085 @default.
• W4285490947 hasConcept C2780030458 @default.
• W4285490947 hasConcept C2780057760 @default.
• W4285490947 hasConcept C530470458 @default.

• next